Is ALGN a Buy or a Sell? The Bull and Bear Case (2026)
Last updated July 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Align Technology (ALGN) rests on Clear-aligner market penetration: Clear aligners still represent a minority of the roughly 500 million people worldwide with malocclusion, leaving a long runway as treatment shifts away from metal braces. The bear case rests on growth has decelerated to low single digits as the North American clear-aligner market matures and consumers pull back on discretionary, often out-of-pocket dental spending during economic softness. Analysts covering it publish targets from $175.00 to $240.00 against a $179.76 price, so even the professionals disagree by 31% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Align Technology is a global medical device company best known for Invisalign, the clear-aligner system that has become the dominant alternative to traditional metal braces, and for iTero, its line of intraoral scanners used to capture digital impressions and plan treatment. The business splits into two segments: Clear Aligner, which generated roughly $3.2 billion of Align's approximately $4.0 billion in fiscal 2025 revenue, and Imaging Systems and CAD/CAM services (iTero and exocad software), which added about $0.8 billion. Align sells primarily through orthodontists and general dentists, and its scanners feed cases directly into the Invisalign workflow, creating a self-reinforcing ecosystem. The investment picture is a high-quality franchise navigating a maturing growth phase. Align holds a leading share of a large, still-underpenetrated clear-aligner market with strong brand recognition and high gross margins near 70 percent, but revenue growth has slowed to low single digits as North America matures and lower-priced rivals expand. Recent results show renewed volume momentum internationally, and the company continues to return cash through buybacks. Because the stock trades at a premium earnings multiple, the debate centers on whether Align can convert its ecosystem advantage and international runway into faster growth while defending pricing.
The bull case: what would have to be true for $240.00
The most optimistic published target on ALGN is $240.00, +33.5% from the $179.76 price as of July 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Clear-aligner market penetration
Clear aligners still represent a minority of the roughly 500 million people worldwide with malocclusion, leaving a long runway as treatment shifts away from metal braces. Align's brand, doctor relationships, and case-management software position it to capture a meaningful share of that expansion. Growth in EMEA, APAC, and Latin America has been running at double-digit rates, offsetting a more mature North America.
2. iTero scanner and digital ecosystem
The iTero scanner line and exocad CAD/CAM software lock doctors into Align's digital workflow, with the majority of Invisalign cases now submitted through digital scans. This razor-and-blade dynamic drives recurring aligner volume and switching costs. New scanner models and AI-assisted treatment tools aim to deepen that ecosystem advantage.
3. Margin profile and capital returns
Align operates with gross margins near 70 percent and generates substantial free cash flow, which it has been directing toward share repurchases, including a fresh $200 million authorization announced in early 2026. Manufacturing scale in lower-cost regions supports profitability. Disciplined cost management gives the company flexibility to invest in growth while returning cash.
4. Adult and teen segment expansion
Align continues to broaden its addressable base, with growth in adult patients seeking discreet treatment and in teens and younger patients where clear aligners are displacing braces. Product features aimed at complex cases expand the range of treatments aligners can address. Direct-to-consumer marketing and doctor-education programs support demand across both cohorts.
The bear case: what would have to be true for $175.00
The most pessimistic published target is $175.00, -2.6% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Align Technology is worth if the risks below bite instead of the drivers above.
Growth has decelerated to low single digits as the North American clear-aligner market matures and consumers pull back on discretionary, often out-of-pocket dental spending during economic softness. Competition is intensifying from lower-priced systems such as Straumann's ClearCorrect, Dentsply Sirona's SureSmile, and Envista's Spark, which can pressure both volume and pricing. Align manufactures aligners in Mexico and ships them to the United States, exposing it to tariff and trade-policy shifts, and a large portion of revenue is international, adding foreign-exchange sensitivity. The premium valuation leaves little room for disappointment, so a growth stumble can drive an outsized share reaction. Patent expirations over time may further lower barriers to entry for competitors.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding ALGN already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on ALGN
14 analysts cover ALGN, with an average target of $210.29 (+17.0% against $179.76) and a split of 11 buy, 4 hold, 1 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the ALGN forecast and price target page.
How is ALGN valued? (as of July 2026)
Snapshot for ALGN as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (FY2025): ~$4.0B
- Revenue (Q1 2026): ~$1.04B, up ~6% YoY
- Q1 2026 EPS: ~$1.57
- Gross margin: ~71%
- Market cap: ~$13B
- P/E ratio: ~30x
As of July 2026, Align posted roughly $4.0 billion in fiscal 2025 revenue and around $1.04 billion in the first quarter of 2026, up about 6 percent year over year with record Invisalign shipments. The stock trades near a market capitalization of $13 billion at a price-to-earnings multiple around 30 times, a premium that reflects the company's leadership and margins but also assumes a return to healthier growth. The company reaffirmed its 2026 guidance and authorized a new $200 million buyback.
How do you decide if ALGN is a buy?
Rather than asking whether ALGN is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ALGN indirectly through an index or sector ETF before adding more.
What would change your mind on ALGN
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Clear-aligner market penetration stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: growth has decelerated to low single digits as the North American clear-aligner market matures and consumers pull back on discretionary, often out-of-pocket dental spending during economic softness fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the ALGN stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ALGN against your real portfolio and see your actual exposure before deciding.
Investing in Align Technology with AI
Connect the broker you already use and ask Walnut's AI how ALGN fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is ALGN a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Clear-aligner market penetration, with revenue (fy2025) at ~$4.0B. The bear case rests on growth has decelerated to low single digits as the North American clear-aligner market matures and consumers pull back on discretionary, often out-of-pocket dental spending during economic softness. Analysts covering it are spread from $175.00 to $240.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell ALGN?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Growth has decelerated to low single digits as the North American clear-aligner market matures and consumers pull back on discretionary, often out-of-pocket dental spending during economic softness. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $175.00, -2.6% from the $179.76 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for ALGN?
+
Clear-aligner market penetration. Clear aligners still represent a minority of the roughly 500 million people worldwide with malocclusion, leaving a long runway as treatment shifts away from metal braces. The most optimistic analyst target on ALGN is $240.00, +33.5% from the $179.76 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for ALGN?
+
Growth has decelerated to low single digits as the North American clear-aligner market matures and consumers pull back on discretionary, often out-of-pocket dental spending during economic softness. Competition is intensifying from lower-priced systems such as Straumann's ClearCorrect, Dentsply Sirona's SureSmile, and Envista's Spark, which can pressure both volume and pricing. Align manufactures aligners in Mexico and ships them to the United States, exposing it to tariff and trade-policy shifts, and a large portion of revenue is international, adding foreign-exchange sensitivity. The premium valuation leaves little room for disappointment, so a growth stumble can drive an outsized share reaction. Patent expirations over time may further lower barriers to entry for competitors. The most pessimistic published target is $175.00, -2.6% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Align Technology do?
+
Align Technology is a global medical device company best known for Invisalign, the clear-aligner system that has become the dominant alternative to traditional metal braces, and fo
What would have to change for ALGN to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Clear-aligner market penetration) stalling in the reported numbers rather than in the narrative, the risk above (growth has decelerated to low single digits as the North American clear-aligner market matures and consumers pull back on discretionary, often out-of-pocket dental spending during economic softness) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Align Technology do?
+
Align Technology makes Invisalign clear aligners, which straighten teeth as a discreet alternative to metal braces, and iTero intraoral scanners plus exocad software used by dentists and orthodontists to capture digital impressions and plan treatment. Clear aligners are the large majority of its revenue.
How does Align make money?
+
Most revenue comes from selling Invisalign aligners to orthodontists and general dentists, who treat patients. A smaller but meaningful share comes from selling iTero scanners and CAD/CAM software, which feed cases back into the aligner business and create recurring demand.
How big is Align Technology?
+
As of July 2026, Align generated roughly $4.0 billion in fiscal 2025 revenue and carried a market capitalization near $13 billion, making it one of the larger companies in the medical device and dental equipment space.
Walnut is informational, not investment advice, and gives no verdict on ALGN. Analyst targets referenced here come from a July 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.